In Brief: Product liability
This article was originally published in The Gray Sheet
Executive SummaryProduct liability: Senate fails twice to invoke cloture May 4 on a substitute amendment offered by Sen. Slade Gorton (R-Wash.) to the product liability bill, HR 956. The substitute is a heavily amended version of the original Gorton/Rockefeller bill (S 565). The first vote (46-53) to limit debate fell short of the necessary 60 votes, with two Democrats, Sens. Joseph Lieberman (Conn.) and James Exon (Neb.), breaking ranks. In the second vote (47-52), Republican Strom Thurmond (S.C.) switched his vote in favor of cloture. Senate Majority Leader Robert Dole (R-Kan.) indicated before the votes that in the event of no cloture, another Gorton/Rockefeller amendment would be considered as a substitute; GOP leadership indicated that the measure is likely to be considered again the week of May 8...
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.